Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.

This study identifies substance P, TNFα, and IFNγ as novel regulators of prolactin and its receptor expression in human skin, suggesting intracutaneous prolactin is not controlled by dopamine.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.

This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.

This review investigates how various intrinsic factors—such as growth factors, cytokines, chemokines, and interferons—regulate hair growth through evidence gathered from in vitro and in vivo studies, highlighting the need for further research in human subjects to validate these findings.

In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.

This study found that patients with Alopecia Areata had significantly higher levels of the chemokines MIG and IP-10 compared to healthy controls, suggesting these molecules may serve as potential biomarkers for diagnosing and monitoring the condition.

In this experimental study, laser irradiation significantly altered the gene expression of cytokines in cultured human T-cell lymphocytes, suggesting that such laser light may photobiomodulate cytokine production in vitro.

In this study, serum IL-13 and TGF-β concentrations were significantly different between alopecia areata patients and controls, suggesting a role for these cytokines in the disease's pathogenesis.

This study observed that interferon β secreted by dermal papilla cells may negatively regulate the growth of outer root sheath cells in hair follicles.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study found that in alopecia areata, epidermal γδ T cells and macrophages contribute to the disease alongside CD8 T cells, with the expression of BST2 marking interferon-driven immune activation in both mouse and human skin, which decreases following treatment with the JAK inhibitor tofacitinib.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

This study found that cutaneous ulcers caused by interferon are not associated with the medication's dosage.

This article reports on a partial regrowth of scalp hair in a patient treated with extracorporeal photochemotherapy and interferon α 2a, but provides no new clinical outcomes.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

During treatment with interferon/ribavirin for hepatitis C, this study observed significant and lasting improvement in a patient's psoriasis without additional psoriasis-specific therapies.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.